Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently
Relocated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical themes, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published anumber of experimental research articles and theoretical papers as sole
Author. These sole-author publications
Included two important topics.
The first of these explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Validation their resistance. The results and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research methodology to come up with knowledge by
Uniting a few facts together from seemingly unrelated areas.
This results in new notions with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable outcome revealed by Dr.Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklony

Has studied the prevention of cancer (an age-related disease) by
Inhibiting organism aging — in other words, “preventing cancer
Via remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Drugs beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including a few models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging medicines to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://www.crunchbase.com/person/mikhail-blagosklonny#section-overview
https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899
https://www.eurekalert.org/pub_releases/2019-04/imi-dg040919.php